Literature DB >> 7617175

Copolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability.

J S Wolinsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7617175     DOI： 10.1212/wnl.45.7.1245

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  8 in total

Review 1.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

2.  Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel.

Authors:  A D Korczyn; P Nisipeanu
Journal:  J Neurol       Date:  1996-04       Impact factor: 4.849

3.  Risk-benefit assessment of glatiramer acetate in multiple sclerosis.

Authors:  T Ziemssen; O Neuhaus; R Hohlfeld
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model.

Authors:  Kuriko Kagitani-Shimono; Ikuko Mohri; Yasushi Fujitani; Kinuko Suzuki; Keiichi Ozono; Yoshihiro Urade; Masako Taniike
Journal:  J Neuroinflammation       Date:  2005-04-06       Impact factor: 8.322

Review 5.  Multiple Sclerosis: Immunopathology and Treatment Update.

Authors:  Narges Dargahi; Maria Katsara; Theodore Tselios; Maria-Eleni Androutsou; Maximilian de Courten; John Matsoukas; Vasso Apostolopoulos
Journal:  Brain Sci       Date:  2017-07-07

6.  Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience.

Authors:  Tatiana de Melo Gomes de Oliveira; Ana Patricia Peres Fiore; Yára Dadalti Fragoso
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

Review 7.  An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.

Authors:  Neeta Garg; Thomas W Smith
Journal:  Brain Behav       Date:  2015-08-03       Impact factor: 2.708

Review 8.  Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action.

Authors:  Kavitha Damal; Emily Stoker; John F Foley
Journal:  Biologics       Date:  2013-11-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.